Moreover, a novel small molecule activator of PP2A (SMAP) elicits antitumor efficacy comparable to Akt allosteric inhibitor (MK2206) in blocking the tumorigenic effects driven by Aldob deficiency in vitro and in vivo. Here, AKT1 is linked to hereditary fructose intolerance.